Type
. [Situation of global leprosy]. Nihon Hansenbyo Gakkai zasshi = Japanese journal of leprosy : official organ of the Japanese Leprosy Association. 2006;75(1):41-9.
Type
. [Future strategies for global leprosy control]. Nihon Hansenbyo Gakkai zasshi = Japanese journal of leprosy : official organ of the Japanese Leprosy Association. 2006;75(1):23-39.
Type
. [Leprosy and medicine I--proposal of an isolation policy and its background]. Nihon Hansenbyo Gakkai zasshi = Japanese journal of leprosy : official organ of the Japanese Leprosy Association. 2006;75(1):3-22.
Type
. Treatment of leprosy: science or politics?. Tropical medicine & international health : TM & IH [Internet]. 2006;11(3):268-78. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-3156.2006.01561.x/pdf
Type
. Sulfanilamide in the treatment of leprosy. 1942. Public health reports (Washington, D.C. : 1974). 2006;121 Suppl 1:221-3; discussion 220.
Type
. Olfactory dysfunction in leprosy. The Laryngoscope. 2006;116(3):413-6.
Type
. The expression of RAGE and EN-RAGE in leprosy. The British journal of dermatology. 2006;154(4):594-601.
Type
. ML0405 and ML2331 are antigens of Mycobacterium leprae with potential for diagnosis of leprosy. Clinical and vaccine immunology : CVI [Internet]. 2006;13(3):333-40. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1391965/pdf/0365-05.pdf
Type
. Genetic susceptibility to mycobacterial disease in humans. Immunology and cell biology. 2006;84(2):125-37.
Type
. Coming in from the cold. BMJ (Clinical research ed.) [Internet]. 2006;332(7540):508. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1388123/pdf/bmj33200508.pdf